6th RNA-Targeted Drug Discovery and Development Summit

2023 has seen advances in artificial intelligence, screening tools and progression into the clinic coupled with numerous strategic collaborations and investments into early discovery has re-fuelled the need to discover selective small molecules to drive drug development forward.

In this context, the RNA Targeted Drug Discovery and Development Summit returns for its 6th year as the most comprehensive, end-to-end meeting, uniting 200+ RNA targeting experts to explore how the latest technologies are improving target validation to fast-track lead optimization and overcoming species difference challenges so more safe and effective drugs can advance into the clinic.


URLs:
Website: https://go.evvnt.com/1893462-0?pid=10018
Tickets: https://go.evvnt.com/1893462-2?pid=10018
Brochure: https://go.evvnt.com/1893462-3?pid=10018

Prices:
Conference + Focus Day - Drug Developer Pricing: USD 4946.00,
Conference + Workshop Day - Drug Developer Pricing: USD 4946.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Focus Day - Academic Pricing: USD 4246.00,
Conference + Workshop Day - Academic Pricing: USD 4246.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + Focus Day - Vendor Pricing: USD 6046.00,
Conference + Workshop Day - Vendor Pricing: USD 6046.00,
Conference Only - Vendor Pricing: USD 3799.00

Speakers: Peng Yue, Chief Executive Officer and Co-Founder, ReviR Therapeutics , Tom Chappie, Senior Principal Scientist and Associate Fellow - Research, Pfizer, Amanda Hargrove, Assistant Professor, Chemistry, Duke University, Paul August, Chief Scientific Officer, ReviR Therapeutics , Adrian Sanborn, Founding Scientist and Biosciences Lead, ATOMIC AI, Matthew Jones, Head of Platform Technology, NextRNA Therapeutics, Katie Warner, Head of RNA Biology, Ribometrix, Shinnuchi Kashida, Co-Founder, Representative Director, President and Chief Executive Officer, xFOREST Therapeutics, Kimberly Robasky, Associate Director, Machine Learning and Artificial Intelligence, Arrakis Therapeutics , Matt Woll, Vice President and Head of Chemistry, PTC Therapeutics, Quentin Vicens, Assistant Professor, University of Houston, Isaac Kimsey, Vice President of Drug Discovery, Base4 Biotechnology, Peter Smith, Co-Founder, President and Chief Executive Officer, Remix Therapeutics, Yochi Slonim, Chief Executive Officer, Anima Biotech, Kerstin Effenberger, Principal Scientist, Discovery Biology, PTC Therapeutics, Jackie Salotti, Principal Scientist, ReviR Therapeutics, Martina Roos, Co-founder and Chief Executive Officer, Sardona Therapeutics, Simon Xi, Chief Executive Officer, Rgenta Therapeutics, Haishan Xiong, Chief Executive Officer, Panorama Medicine, Anu Bhattacharyya, Executive Director Biology/Nucleotide Repeat Disorders, PTC Therapeutics, Irina Tuszynska, Leader of Bioinformatics Group, Molecure, Dominic Reynolds, Senior Vice President, Drug Discovery, Remix Therapeutics, Franz Obermayer, Chief Executive Officer, EPICS Therapeutics , Matthew Daniels, Associate Director, Accent Therapeutics, Mark Ledeboer, Senior Vice President, Drug Discovery, Expansion Therapeutics , Eric Westhof, Professor, Institut de biologie moleculaire et cellulaire du CNRS, Universite de Strasbourg, France, Tamara Reyes-Robles, Principal Scientist, Ananke Therapeutics, Li Zhang, Director of Quantitative Clinical Pharmacology, Daiichi Sankyo, Balajee Somalinga, Director, RNA Biology, CHDI Foundation , Pascale Beurdeley, Senior Vice President, Product Development, Depixus